Zaria Cancer Consortium

655 posts

Zaria Cancer Consortium banner
Zaria Cancer Consortium

Zaria Cancer Consortium

@Zariacancerco11

To have a holistic approach involving diverse stakeholders towards improving cancer care outcomes and research in Africa.

Zaria, Nigeria Katılım Ocak 2022
1.1K Takip Edilen952 Takipçiler
Zaria Cancer Consortium retweetledi
Advanced Prostate Cancer Consensus Conference
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors: @Silke_Gillessen @fabioturco92 @Prof_IanD @drjefstathiou Karim Fizazi @Prof_Nick_James Neal Shore Eric Small Matthew Smith @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti Muhammad Bulbul Consuelo Buttigliero Orazio Caffo @cdanicas @Ecastromarcos Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono @mdesantis234 @nachoduranm @EfstathiouEleni Onyeanunam N. Ekeke Tamer I.H. El Nahas @drlouiseemmett @stefanofanti4 Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong @fontev1 @Nicola_Fossati Daniel J. George @marty_gleave Gwenaelle Gravis Susan Halabi Daniel Heinrich @ProfKHerrmann @DrMHofman Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain @BarbaraJereczek Robert J. Jones Anthony M. Joshua @ravikanesvaran Daniel Keizman @FacsRaja Gero Kramer @LoebStacy Brandon A. Mahal Fernando C. Maluf 75 76, @quimmateo David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80, @DrRanaMcKay Niven Mehra 82, @amerseburger @CaPsurvivorship , Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji @declangmurphy Vedang Murthy Shingai B.A. Mutambirwa @DrPaulNguyen William K. Oh @piet_ost Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule @DrSpratticus Sandy Srinivas @cnsternberg Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura @DrYukselUrun Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero @AOmlin
Advanced Prostate Cancer Consensus Conference tweet media
English
4
115
238
42.5K
Zaria Cancer Consortium
Zaria Cancer Consortium@Zariacancerco11·
Improving access, education, and collaboration is crucial to address these challenges and better cancer overall survival rates from prostate cancer among Black men globally.
English
0
0
1
14
Zaria Cancer Consortium
Zaria Cancer Consortium@Zariacancerco11·
September prostate cancer awareness! Black men face a higher incidence & mortality rate of prostate cancer due to in part disease-associated genetic variants, limited access to healthcare infrastructure, medicine, and technologies, and cultural barriers... @BIOVentures @CaPTC7
Zaria Cancer Consortium tweet mediaZaria Cancer Consortium tweet mediaZaria Cancer Consortium tweet media
English
1
0
1
31
Zaria Cancer Consortium retweetledi
Oluwaseyi Toye
Oluwaseyi Toye@nijitoye·
Together we can change the narrative.
NICRAT@NicratGov

𝗙𝗚 𝗲𝗻𝗴𝗮𝗴𝗲𝘀 𝗠𝗮𝘆𝗼 𝗰𝗹𝗶𝗻𝗶𝗰, 𝗠𝗶𝗹𝗸𝗲𝗻 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝘁𝗼 𝗯𝗼𝗼𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 The Federal Government is collaborating with the Mayo Clinic and the Milken Institute to improve cancer research, training of oncologist, building Capacity in Clinical trials, and Cancer Genomics and Precision Oncology. To this end the National Institute for Cancer Research and Treatment NICRAT held a symposium on Cancer Genomic, precision Oncology Care and Community health for black population, under the theme, discover, innovate and collaborate. Cancer Genomics involves studying the genetic changes in Cancer Cells by allowing greater insights into prevention, early detection, treatment, prognosis and recurrence, while Precision Oncology is choosing treatment for cancer patients based on the DNA signature of an individual patient’s tumour. Beyond the identification of individual targetable alterations, genomic methods measure cancer mutational load, and identify cancer- specific proteins that inform the design of personalised anti-cancer medications. The Minister of state for health, Dr. Tunji Alausa, while declaring the Symposium open pointed out that the alarming burden of Cancer in recent times underscores an urgent need to move beyond conventional cancer treatment to innovative treatment regimen that suit the unique needs of any cancer patient. According to Dr. Alausa, the Nigeria Government recognise the potential of precision Medicine to revolutionalise Nigeria Healthcare Value Chain, improve cancer care outcomes hence the need for the partnership with the renowned cancer facilities such as the Mayo Clinic and Milken Institute. “It is imperative therefore that we embrace precision oncology care and understand the genetic and molecular landscape of cancers in African Black populations which will enable the development of more effective and less toxic cancer treatments in Nigeria” “Research in cancer genomics has revolutionalised our understanding of cancer development and progression. Emerging clinical applications of Cancer genomics also includes monitoring treatment responses and characterising mechanisms of resistance. As a nation, we cannot but ensure that we are part of this revolutionary movement to improve the quality and outcome of cancer care in our population” The Minister described the Symposium as a significant step towards a future where cancer care is truly personalised, every life valued and every patient story is one of hope and triumph. The DG of the National Institute for Cancer Research and Treatment, Prof Usman Aliyu Malami, said the event was a step in the journey to making cancer treatment more precise, targeted and culturally relevant. “This symposium is an opportunity to engage with World renowned cancer experts and forge strategic partnerships through shared knowledge and exchange of ideas and explore the latest advancement in cancer genomics and precision Oncology” The Executive Director of the Mayo Clinic, Dr. Cheryl Willman, said under the partnership, they would support Nigeria to shift from treatment of late-stage Cancer to Cancer Prevention, Early Screening and Detection to save lives, as well as establish a robust Cancer registry in Nigeria. “The creation of a National Cancer Registry in Nigeria is very important to understand which cancers are increasing in incidence, which cancers are increasing in mortality and allows the country to know how to invest in diagnostic cancer equipment” The Symposium on” Cancer Genomic, Precision Oncology care and precision community health for black population”” was organised by NICRAT in collaboration with the Mayo Clinic and Milken Institute. #CancerGenomics #cancerresearch #CancerTreatment

Ilorin, Nigeria 🇳🇬 English
0
3
5
194
Zaria Cancer Consortium retweetledi
NICRAT
NICRAT@NicratGov·
𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀, 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗖𝗮𝗿𝗲 𝗮𝗻𝗱 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗛𝗲𝗮𝗹𝘁𝗵 𝗳𝗼𝗿 𝗕𝗹𝗮𝗰𝗸 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀: 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿, 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗲 & 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲 #nicratupdate #CancerGenomics #cancerprevention #CancerControl
NICRAT tweet media
English
0
5
22
379
Zaria Cancer Consortium retweetledi
Fumiko Ladd Chino, MD, FASCO
Fumiko Ladd Chino, MD, FASCO@fumikochino·
In a large cohort of pts with GI cancers screened for #financialtoxicity & health related social risks, over HALF were identified to have significant financial burdens & over ONE FOURTH had an unmet essential need. Dr @KaitlynLapen presented yesterday afternoon #ASCO24
Fumiko Ladd Chino, MD, FASCO tweet media
English
1
14
38
6K
Zaria Cancer Consortium retweetledi
Fumiko Ladd Chino, MD, FASCO
Fumiko Ladd Chino, MD, FASCO@fumikochino·
Pts with #breastcancer report good provider communication skills overall... But side effect profiles are not always well-explained. This matters bc pts who reported poor communication were 64% less likely to take all recommended #bcsm care #ASCO24: tweetorial coming later!
Fumiko Ladd Chino, MD, FASCO tweet media
English
2
5
14
1.6K
Zaria Cancer Consortium retweetledi
Noemi Reguart
Noemi Reguart@NReguart·
Second practice changing trial of the day: ADRIATIC Durva consolidation vs plb after cCRT in LS-SCLC. Dual P. endpoints OS/PFS meet (3-y FUP): 24 mo OS gain (median 55.9 vs 33.4, HR 0.73) and 24% reduction in the risk of PFS/death (median 16.6 vs 9.2 mo, HR 0.76) #ASCO24 #LCSM
Noemi Reguart tweet mediaNoemi Reguart tweet mediaNoemi Reguart tweet mediaNoemi Reguart tweet media
English
2
43
101
9K
Zaria Cancer Consortium retweetledi
Arndt Vogel
Arndt Vogel@ArndtVogel·
🔥PLENARY Session #ASCO24🔥 Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus 🔎 ESOPEC phase III trial, 438 patients 👉R0 180 vs 171 👉pCR 17 vs 10% 👉mOS 66 vs 37 mo 👉3yr OS: 57.4 vs 50.7% 🧐FLOT improves OS compared to CROSS @myESMO
Arndt Vogel tweet mediaArndt Vogel tweet mediaArndt Vogel tweet mediaArndt Vogel tweet media
English
7
150
301
51.6K
Zaria Cancer Consortium retweetledi
Mark Lewis, MD, FASCO
Mark Lewis, MD, FASCO@marklewismd·
Not every day that you get to celebrate a years-long survival advantage in the treatment of small cell lung cancer!!! Mind-blowing to see the median overall survival for limited stage SCLC approach the oncologically conventional 5-year milestone #lcsm #ASCO24
Mark Lewis, MD, FASCO tweet media
English
10
56
324
37.9K
Zaria Cancer Consortium retweetledi
Zainab Shinkafi-Bagudu
A wonderful evening with my @AORTIC_AFRICA family. Many issues raised around research in Africa. Comforting that organizations like @ASCO @NCIResearchCtr are actively funding and creating opportunities for researchers in Africa. #ASCO24
Zainab Shinkafi-Bagudu tweet mediaZainab Shinkafi-Bagudu tweet mediaZainab Shinkafi-Bagudu tweet mediaZainab Shinkafi-Bagudu tweet media
English
4
23
68
4.9K
Zaria Cancer Consortium retweetledi
Zaria Cancer Consortium retweetledi
CaPTC
CaPTC@CaPTC7·
Our very own @PinkyProf turns 70 on March 8. Please use the information below to register to attend any, or both of the webinars advertised👇
CaPTC tweet media
English
1
3
6
396
Zaria Cancer Consortium retweetledi
Ameenah Marafa
Ameenah Marafa@Marafa_Aminat·
The Coordinator, Kano Cancer Care Centre @AminuMagashiG conducting an orientation on Cancer Awareness to the Senior Special Reporter and Special Reporter to H.E. the governor of Kano State @Kyusufabba on Cancer Centre.
Ameenah Marafa tweet mediaAmeenah Marafa tweet media
English
0
5
7
232
Zaria Cancer Consortium retweetledi
Yehoda Martei MD, MSCE
Yehoda Martei MD, MSCE@ymartei·
Powerful image, illustrating inequity in clinical translation of global oncology research knowledge in Africa, presented by Dr. Gopal at #AORTIC2023
Yehoda Martei MD, MSCE tweet media
English
0
4
12
843